As of May 22, 2025, Impel Neuropharma Inc's estimated intrinsic value ranges from $0.00 to $0.00 per share, depending on the valuation methodology applied.
Valuation Method | Fair Value (USD) | Implied Upside/Downside |
---|
Is Impel Neuropharma Inc (IMPL) undervalued or overvalued?
With the current market price at $0.24, the stock appears to be significantly overvalued.
Intrinsic value represents the "true" worth of a company based on its fundamentals rather than market sentiment. We've employed multiple methodologies to triangulate Impel Neuropharma Inc's intrinsic value, including:
The cost of capital is a critical factor in valuation models, representing the required return for investors.
WACC Component | Low | High |
---|---|---|
Long-term bond rate | 4.2% | 4.7% |
Equity market risk premium | 5.0% | 6.0% |
Adjusted beta | 16.84 | 19.93 |
Cost of equity | 88.4% | 124.7% |
Cost of debt | 5.0% | 5.0% |
Tax rate | 26.2% | 27.0% |
Debt/Equity ratio | 50.28 | 50.28 |
After-tax WACC | 5.3% | 6.0% |
Metric | Value |
---|---|
Market Capitalization | $1M |
Enterprise Value | $-14M |
Trailing P/E | 0.00 |
Forward P/E | 0.00 |
Trailing EV/EBITDA | 0.00 |
Current Dividend Yield | 0.00% |
Dividend Growth Rate (5Y) | 0.00% |
Debt-to-Equity Ratio | 50.28 |
To determine the most reliable intrinsic value estimate, we weigh each valuation method based on:
Valuation Method | Weight | Weighted Value |
---|---|---|
Weighted Average | 100% | $0.00 |
Based on our comprehensive valuation analysis, Impel Neuropharma Inc's weighted average intrinsic value is $0.00, which is approximately 100.0% below the current market price of $0.24.
Key investment considerations:
Given these factors, we believe Impel Neuropharma Inc is currently significantly overvalued with the potential for long-term appreciation based on the company's growth trajectory and financial strength.